Mirtazapin Actavis (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and antagonizes 5‑HT2 and 5‑HT3 receptors. This dual action enhances serotonergic and noradrenergic neurotransmission while reducing certain serotonin‑related side effects, contributing to mood improvement.

The appropriate dose of Mirtazapin Actavis is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Dosage adjustments are made according to therapeutic response and any adverse effects observed.

Mirtazapin Actavis is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are no adequate human studies. It should be used only if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider, as mirtazapine does pass into breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mirtazapine differs from SSRIs and SNRIs by its NaSSA mechanism, which may result in less sexual dysfunction and a distinct side‑effect profile, including sedation and weight gain. It is often chosen when patients experience insomnia or poor appetite, whereas other classes may be preferred for different tolerability considerations.

Mirtazapin Actavis should be stored at ambient temperature below 25 °C, in its original packaging, protected from moisture and direct light. Keep the product out of reach of children and do not use if the packaging is damaged.

The medication is taken orally, typically once daily in the evening, with or without food. It can be swallowed whole or, if appropriate, placed sublingually or buccally as directed by the prescriber. Consistency in the time of administration helps maintain stable plasma levels.

Serious risks include agranulocytosis, severe neutropenia, seizures, hepatic dysfunction, and the emergence of suicidal thoughts, particularly during the initial treatment phase. Patients should be monitored closely for signs of infection, liver abnormalities, or worsening mood.

Mirtazapin Actavis is contraindicated in patients with known hypersensitivity to mirtazapine or any excipients, those currently on MAO inhibitors, and individuals with severe hepatic impairment without dose adjustment. Caution is also advised for patients with a history of bipolar disorder, as it may trigger mood switching.